What АРТРА Treats: Main Uses and Benefits

АРТРА is commonly used in conditions characterized by periods of heightened symptoms and is relevant in contexts marked by increased discomfort related to joint degeneration. The medication primarily supports conditions involving Osteoarthritis (OA) of the knee, hip, and structural issues in the lumbosacral spine. As a structural support agent, it is applied across domains where additional symptomatic support is needed. Long-term use of the active components is associated with assisting in the management of symptoms and supporting functional stability in OA.

The medication helps address symptom clusters that may become intense or disruptive, specifically chronic joint pain (arthralgia) and stiffness that interfere with daily functioning. The treatment is commonly used to help with easing the overall symptom burden and contributing to improved comfort. АРТРА assists with maintaining functional stability and offers symptomatic relief that helps patients cope more steadily with symptom fluctuations, particularly in adult patients managing long-term joint issues.

It is commonly used to help with discomfort arising from functional strain during movement. This supportive use is relevant when symptoms become more noticeable in chronic conditions, assisting with maintaining functional stability and contributing to improved day-to-day comfort.

Quick Fact: Relief for Functional Strain
АРТРА is applied in symptomatic management to help ease the physical discomfort and stiffness that affect mobility during periods of increased functional strain on joints.

Regulatory References

1. Glucosamine and Chondroitin for Osteoarthritis NCCIH - NIH

Populations Excluded or Restricted from Using АРТРА

The eligibility profile for АРТРА (Glucosamine/Chondroitin) strictly defines who can and cannot use the medicine according to official regulatory labeling. The medicine is generally approved for use in the adult population (18+).

Category	Eligibility Status	Basis for Restriction (Official Labeling)
Absolute Contraindications	Must Not Use	Known hypersensitivity to any component or shellfish allergy. Concomitant use with oral Vitamin K antagonists (e.g., Warfarin) is also strictly prohibited.
Age-Related Limits	Not Recommended	Use is not recommended in children and adolescents under 18 years of age, as safety and efficacy have not been established by regulatory authorities.
Reproductive Status	Not Established / Avoid	Use during pregnancy and breastfeeding is not established. Due to a lack of clinical safety data, use during these periods is generally avoided.

Conditions Requiring Caution

Official labeling mandates use with caution and monitoring for certain pre-existing conditions:

• Diabetes Mellitus: Requires close monitoring of blood glucose levels.
• Asthma: Caution is advised, as the medicine may exacerbate symptoms in some individuals.
• Glaucoma: Caution is required due to the potential for increased intraocular pressure.
• Organ Impairment: Patients with renal or hepatic impairment have not been specifically studied and require medical caution, with severe impairment generally advised against.

Interactions with other medicines and products

This information details the officially documented interaction profile of АРТРА (Glucosamine Hydrochloride and Chondroitin Sulfate), strictly based on governmental regulatory documents.

Documented Pharmacodynamic Interaction

The most significant interaction documented in regulatory labeling is with coumarin anticoagulants, such as Warfarin and Acenocoumarol. Post-marketing reports indicate that co-administration may lead to an increase in the International Normalized Ratio (INR), potentially elevating the risk of bleeding events.

Interacting Product Category	Constraint or Requirement
Coumarin Anticoagulants	Close monitoring of INR and other coagulation parameters is required upon initiation, dose adjustment, or discontinuation of the product.

Status of Pharmacokinetic Studies

Formal pharmacokinetic and pharmacodynamic drug interaction studies with most other medications have generally not been performed for this combination product. As a result, there is no official information in the labeling regarding potential interactions mediated by metabolic enzymes (e.g., CYP pathways) or drug transporters.

Population-Specific Notes

The official labeling notes that no specific dose recommendations or interaction guidelines can be provided for patients with impaired renal or hepatic function, due to the absence of dedicated clinical study data in these populations. Individuals with impaired glucose tolerance or diabetes should consult a healthcare professional regarding potential effects on glucose levels.

The action of the combined preparation is defined by its dual, complementary modulation of metabolic processes within the joint structure, specifically targeting both the influence on structural synthesis and the destructive cascade of joint tissue degradation.

Anabolic Precursor Supply for Cartilage Matrix Synthesis

The mechanism involves providing essential substrate and cellular stimulation to the chondrocytes, the cells responsible for creating cartilage. Glucosamine Hydrochloride acts as a fundamental precursor for synthesizing structural macromolecules like proteoglycans and glycosaminoglycans (GAGs). This action, complemented by the stimulating effect of Chondroitin Sulfate, results in a net shift toward increased production of these components, a process that increases the potential for mechanical resilience and water-binding capacity of the articular cartilage.

Modulation of Catabolic and Inflammatory Pathways

The second mechanistic domain focuses on modulating the processes that involve joint tissue degradation. Both active ingredients exert an anti-catabolic effect by suppressing the activity and expression of specific joint-degrading enzymes, such as Matrix Metalloproteinases (MMPs). Furthermore, the compounds modulate the chronic, low-grade inflammatory state by inhibiting key signaling pathways like NF-kappaB, thereby reducing the production of destructive mediators such as Interleukin-1 beta (IL-1beta). This dual suppression contributes to a reduced net rate of extracellular matrix loss and influences the local biochemical balance.

The use of АРТРА, a combination of Glucosamine and Chondroitin Sulfate, is characterized by standardized parameters for its administration and dosing. The medication is delivered via the oral route, typically using film-coated tablets or, for some forms, powder for oral solution. The established adult dosing regimen is designed to provide a total daily intake of Glucosamine 1500 mg and Chondroitin Sulfate 1200 mg. This total dose may be taken as a single administration once daily or as divided doses depending on the specific product strength.

The administration protocol specifies that АРТРА is taken preferably at meals. If the medication is supplied as a powder for oral solution, it must be dissolved completely in a glass of water prior to consumption. The treatment follows a structured course duration, rather than indefinite use. Usage parameters indicate that continued use should be subject to re-evaluation by a healthcare provider, particularly if effects are not noted after an initial period of two to three months. Regarding specific populations, it is generally stated that the preparation is not recommended for use in children and adolescents under 18 years of age, as safety data for this group remains unavailable. Dose adjustments are generally not required for otherwise healthy older adults.

Research Evidence / Overview of Studies for АРТРА

Evidence for Use in Osteoarthritis of the Knee and Hip

The combination of Glucosamine and Chondroitin, the active components in АРТРА, was evaluated in research exploring the condition of Osteoarthritis (OA), particularly of the knee and hip joints. Researchers conducted many Randomized Controlled Trials (RCTs) and subsequently analyzed these trials through systematic reviews and meta-analyses. These studies primarily focused on adults and older adults diagnosed with OA.

The main outcomes research examined related to patient-reported discomfort (pain intensity) and functional limitations (stiffness and activity level). The research explored how symptoms evolved in the observed populations during the short- to intermediate-term study periods, often lasting between six months and two years.

Findings were mixed across the large number of trials. Some trials reported patterns of change in measured outcomes related to physical discomfort. However, other high-quality trials found little to no difference between the active preparation and the placebo. Independent scientific reviews often report that this body of evidence remains heterogeneous—meaning the results apply only to the specific populations studied and vary significantly depending on the trial methodology.

---

Long-Term Studies and Follow-Up Data

Research has explored the effects of the active components over defined time intervals that extend beyond a year. One goal of the extended research was to monitor whether the preparation was associated with differences in the rate of structural progression of the disease, measured using radiography to examine Joint Space Width (JSW). Additionally, some long-term post-marketing studies have tracked the rate of major clinical events, such as the need for total knee or hip replacement surgery.

Research describes patterns related to structural outcomes are uncertain and certainty remains low. Studies aiming to assess the impact on JSW have yielded conflicting results. This means the long-term effects are not fully established regarding structural change, although the extended research provides some context but not individual predictions about major surgical outcomes.

---

What Is Still Uncertain About the Research for АРТРА

Evidence is limited for long-term outcomes, particularly concerning the sustained effect on pain and physical function beyond two years. The follow-up durations were limited in many of the key studies. Furthermore, subgroup findings are uncertain. There is limited information available for how results may apply to patients with different levels of disease severity. Research highlights what is known and what is still uncertain; study results reflect the specific conditions under which they were conducted, and findings describe group patterns, not personal outcomes.

Key Studies & References

1. Glucosamine and Chondroitin for Osteoarthritis: What You Need To Know (NCCIH - NIH)

Common questions about АРТРА (FAQ)

Q: How is АРТРА different from similar products that contain only Glucosamine?

A: АРТРА is a combination preparation that contains both Glucosamine and Chondroitin Sulfate. Regulatory information states that Glucosamine acts as a building block for cartilage components, while Chondroitin Sulfate is a structural component that provides resistance to compression. This combination is intended to offer a dual, complementary action in supporting joint structure.

Q: Can individuals with a history of heart conditions or high blood pressure use АРТРА?

A: Official safety information notes reports of irregular heartbeats and swelling in the legs as rare adverse effects. Due to the potential for effects on blood pressure and heart function, caution is suggested for individuals with pre-existing heart conditions or high blood pressure. Concerns or changes in symptoms are typically reviewed by a healthcare professional.

Q: Does АРТРА interact with common over-the-counter pain relievers or NSAIDs?

A: Formal drug interaction studies with most medications, including common pain relievers, have generally not been performed according to regulatory documents. The only primary documented interaction is with coumarin anticoagulants (blood thinners), for which monitoring is specified in the regulatory labeling.

Q: Are there any documented interactions between АРТРА and food or alcohol?

A: The official administration guidance recommends taking the medicine preferably at meals to help minimize potential stomach upset. Furthermore, consumption of alcohol while using the medicine is generally advised against in official patient information to avoid potential unpleasant side effects.

Q: How long does it typically take for a person to experience the expected effects of АРТРА?

A: The product is classified as a Symptomatic Slow-Acting Drug for Osteoarthritis (СИСАДОА). Studies show that relief of symptoms, particularly pain, may not be experienced until after some weeks of treatment. Because of this classification, the timeframe for re-evaluation is often set at 2-3 months before a noticeable effect on symptoms is typically noted.

Q: What is the procedure described in official materials if a dose of АРТРА is forgotten?

A: According to official regulatory instructions, if a dose is forgotten, patients are advised to skip the missed dose and continue with their regular schedule. Regulatory documents state that double or extra doses should not be taken to compensate for a missed one.

Q: Is there evidence to support the use of АРТРА for all different forms of joint pain?

A: The primary focus of clinical evaluation and regulatory approval is for the symptoms of Osteoarthritis (OA), particularly of the knee and hip joints. Official documentation does not establish evidence to support its use for other forms of joint pain.

Q: What are the excipients or non-active ingredients contained in the АРТРА tablet?

A: The full list of non-active ingredients (excipients) is detailed in the official prescribing information and patient leaflet. These can include common components like sodium, aspartame (Е951), and sorbitol (Е420), depending on the specific dosage form. For individuals with specific ingredient sensitivities, such as Phenylketonuria, reviewing this list with a healthcare professional is generally advised.

Q: Why are the Glucosamine and Chondroitin components in АРТРА often described as 'sulfate' salts?

A: The active components are supplied as sulfate (Chondroitin Sulfate) or hydrochloride (Glucosamine Hydrochloride) salts. These chemical forms are commonly used in pharmaceutical manufacturing. Regulatory and technical information indicates that they are chosen to help ensure the medicine's chemical stability and optimal absorption into the body.

Q: Is there a necessity for routine laboratory tests while a patient is using АРТРА?

A: Routine laboratory testing is not explicitly mandated by regulatory bodies for the general population. However, close monitoring of the INR (a measure of blood clotting) is specified in the product labeling for patients taking anticoagulants, and monitoring of blood glucose levels is a requirement for individuals with diabetes.

Q: Does the use of АРТРА come with any warnings regarding the ability to drive or operate machinery?

A: Official warnings note that side effects such as drowsiness may occur in some patients. Regulatory guidance suggests caution when driving or operating machinery. If side effects like drowsiness or dizziness occur, official information states that these activities must be avoided.

Q: What is the difference, if any, between the various dosage forms or strengths of АРТРА available?

A: The product is available in different oral dosage forms, typically film-coated tablets or powder for oral solution. These forms may vary in specific inactive ingredients, the required administration method (swallow versus dissolve), and the administration schedule (e.g., single daily dose versus divided doses).

Q: What does official guidance suggest a patient should do if they experience a listed side effect?

A: For most common, minor side effects, continued use is generally acceptable. However, official guidance states that patients must contact a healthcare provider immediately if they experience any severe adverse reactions. Examples of severe reactions include signs of a serious allergic reaction or irregular heartbeats.

Q: What is the documented shelf life of the medicine АРТРА after purchase?

A: The official shelf life (expiry date) is printed directly on the outer packaging and on the blister foil. This date indicates the time until which the product is considered stable and effective. Official guidelines indicate that the medicine must be discarded after this expiration date.

Q: Why do official sources often recommend a period of observation before determining the success of АРТРА therapy?

A: The long observation period (2-3 months) is recommended because the product is classified as a Symptomatic Slow-Acting Drug for Osteoarthritis (СИСАДОА). Its mechanism involves stimulating cartilage support processes, which takes time. This means its effect on joint support and subsequent symptom relief is typically not immediate.

Q: Does the use of АРТРА have any effect on blood pressure?

A: Official safety profiles indicate a potential for elevated blood pressure with the use of Chondroitin Sulfate, one of the active components. Although not frequently reported, for individuals with pre-existing hypertension, monitoring blood pressure is noted as a necessary precaution.

Q: Is there any known risk of developing physical or psychological dependence on АРТРА?

A: Based on the pharmacological class of the product and its active ingredients, the official safety profile for the medicine does not indicate a risk of developing physical or psychological dependence or abuse.

Q: How are the active components in АРТРА sourced and what assurance of quality is provided?

A: Regulatory labeling confirms that the active ingredient Glucosamine is often obtained from shellfish, which is the basis for the shellfish allergy contraindication. The medicine is manufactured under strict regulatory standards known as Good Manufacturing Practice (ГМП), which ensures quality control.

Q: Can АРТРА be taken alongside medications prescribed for cholesterol management?

A: Clinical studies have been conducted to evaluate the effects of Glucosamine alongside common statin medications (for example, simvastatin or atorvastatin). These studies showed no significant changes in cholesterol levels. No specific interactions with cholesterol-lowering drugs are detailed in the official regulatory warnings.

Q: Is there any official information about АРТРА that suggests the effects may wear off after stopping treatment?

A: Clinical trials have noted that the treatment may provide a residual therapeutic effect even after use has been discontinued. This residual effect is typically evident for up to two months following drug withdrawal, after which the structural support effects may begin to diminish.

Q: What are the official guidelines for reducing or stopping the use of АРТРА?

A: The treatment is intended to be taken as a structured course, and discontinuation is typically discussed during the re-evaluation with a healthcare provider. Furthermore, official safety warnings require the medicine to be explicitly discontinued at least two weeks before any planned surgical or dental procedure.

Q: What is the distinction between chondroitin sulfate and other forms of chondroitin found in supplements?

A: The specific component present in АРТРА is Chondroitin Sulfate. This is the form naturally found in cartilage and is the subject of official regulatory clinical research. The evidence supporting the medication's intended action is based on the use of this specific sulfated form.

Q: How is the potential for drug abuse or misuse described for АРТРА in official documents?

A: Official drug safety profiles for this product and its class of active ingredients include standard evaluations for abuse potential. Regulatory documentation does not list any specific warnings or documentation regarding the potential for drug abuse or misuse.

Q: How is the risk of overdose described in the official patient information for АРТРА?

A: In case of accidental or intentional overdose, any symptoms experienced are likely to be an exaggeration of the known side effects, such as increased nausea or diarrhea. Official guidance states that in the event of an overdose, individuals should seek emergency medical attention or contact a poison control center immediately.

How to Store and Dispose of АРТРА

Storage and disposal requirements for АРТРА tablets are based on ensuring product stability and safety, as outlined in regulatory documentation.

---

Official Storage Requirements

Condition	Requirement
Temperature	Store at a controlled room temperature, not exceeding 30 C (86 F).
Protection	The medicine must be protected from moisture and stored in a dry environment.
Container	Keep the medicine in its original container and ensure the container is tightly closed.
Child Safety	It is mandatory to keep the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired АРТРА should be disposed of following local regulatory guidelines. The preferred method is to take the product to an authorized drug take-back location. If a take-back program is unavailable, the medicine should be disposed of in the household trash; it must not be flushed down the toilet or sink.